Skip to main content

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

The Original Article was published on 19 February 2018

Correction to: Mol Cancer

Following publication of the original article [1], the authors reported an error in Table 1. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row).The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.

Table 1 Clinical trials with BTK inhibitors in B cell malignancies


  1. Singh PS, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cellsand malignancies. Mol Cancer. 2018;17:57

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Rudi W. Hendriks.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pal Singh, S., Dammeijer, F. & Hendriks, R.W. Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 18, 79 (2019).

Download citation

  • Published:

  • DOI: